申请人:Abbott GmbH & Co. KG
公开号:US20130116241A1
公开(公告)日:2013-05-09
The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
wherein
Q is O or S, X
1
is N or CH, X
2
is N or C—R
7
; X
3
is O, S—X
4
═C(R
8
)—, where C(R
8
) is bound to the carbon atom which carries R
2
, or —X
5
═C(R
9
)—, where X
5
is bound to the carbon atom which carries R
2
; X
4
is N or C—R
9
; X
5
is N;
Het is selected from optionally substituted phenyl, monocyclic hetaryl and fused bicyclic hetaryl;
R
1
is selected inter alia from hydrogen, halogen, OH, C
1
-C
4
-alkyl, trimethylsilyl, C
1
-C
4
-alkylsulfanyl, C
1
-C
4
-alkoxy-C
1
-C
4
-alkyl, C
1
-C
4
-alkoxy, C
1
-C
4
-alkoxy-C
1
-C
4
-alkoxy, the moiety Y
1
-Cyc
1
;
R
2
is selected inter alia from hydrogen, halogen, OH, C
1
-C
4
-alkyl, trimethylsilyl, C
1
-C
4
-alkoxy-C
1
-C
4
-alkyl, C
1
-C
4
-alkoxy, C
1
-C
4
-alkoxy-C
1
-C
4
-alkoxy, C
2
-C
4
-alkenyloxy, etc;
A represents one of the following groups A
1
, A
2
, A
3
, A
4
or A
5
:
where * indicates the points of attachment to Het and to the nitrogen atom, respectively;
and where R
3
to R
9
, R
3e
, R
3f
, A′, Y
1
and Cyc
1
are defined in the claims.
本发明涉及公式I的新化合物,它们是
磷酸二酯酶10A的
抑制剂,并用于制造药物,因此适用于治疗或控制神经和精神障碍等医学疾病,改善与此类疾病相关的症状并降低此类疾病的风险。其中Q为O或S,X1为N或CH,X2为N或C-R7;X3为O,S-X4═C(R8)-,其中C(R8)与携带R2的碳原子相连,或-X5═C(R9)-,其中X5与携带R2的碳原子相连;X4为N或C-R9;X5为N;Het选自可选取代的苯基,单环杂环和融合的双环杂环;R1选自氢,卤素,OH,C1-C4烷基,三甲基
硅基,C1-C4烷基
硫醇基,C1-C4烷氧基-C1-C4烷基,C1-C4烷氧基,C1-C4烷氧基-C1-C4烷氧基,Y1-Cyc1基团;R2选自氢,卤素,OH,C1-C4烷基,三甲基
硅基,C1-C4烷氧基-C1-C4烷基,C1-C4烷氧基,C1-C4烷氧基-C1-C4烷氧基,C2-C4烯氧基等;A表示以下A1,A2,A3,A4或A5中的一个基团:其中*表示与Het和氮原子的连接点,R3至R9,R3e,R3f,A',Y1和Cyc1在权利要求中被定义。